Self-help Guided by Lay Providers for Anxiety in Older Adults

October 2, 2023 updated by: Philippe Landreville, Laval University

Generalized Anxiety Disorder in Older Adults : Efficacy of a Self-help Treatment Guided by Trained Lay Providers

Few older adults receive treatment for Generalized Anxiety Disorder (GAD) despite a high prevalence in this population and significant associated health care costs. Although older adults generally prefer psychotherapy to medication for help with anxiety, face-to-face psychotherapy is difficult to access for many of them. Psychological guided self-help (GSH), which patients use by themselves at home under the supervision of a licensed mental health provider (e.g., psychologist), has been shown to be effective. However, the capacity of our health care system to respond adequately to the mental health needs of seniors has been questioned and cost-effective solutions are required. Because the therapist's role in GSH is limited to supporting the patient, it is conceivable that this role could be assumed by trained and supervised lay providers (LP) instead of licensed providers. If this approach is effective, it could help provide many older adults with much needed mental health treatment at a lower cost. The main objective of this project is to evaluate the effectiveness of GSH guided by LP for GAD in older adults. Participants will be assigned randomly to an experimental group, which will receive treatment immediately, or to a control group whose treatment will be delayed. Data will be obtained through clinician evaluations and self-assessment questionnaires. They will include socio-demographic characteristics, symptoms of GAD, variables related to anxiety, such as depression and sleep difficulties, and participants' perception of treatment. For the experimental group, data collection will take place at four different times: before treatment begins, after treatment ends, and at 6 and 12 months after the end of treatment. Control group participants will be assessed on three occasions: before and after the waiting period and after receiving treatment. The efficacy of GSH will be established by comparing the change in the two groups on the main variables. We will also identify the characteristics of patients associated with improvement during treatment and document their perception of treatment.

Study Overview

Detailed Description

Few older adults with Generalized Anxiety Disorder (GAD) receive treatment although it is one of the most prevalent anxiety disorders in this population and involves significant health care costs. Studies show that older adults generally prefer psychotherapy and find it more acceptable than medication for help with anxiety. Unfortunately, face-to-face psychotherapy is difficult to access for many of them. Guided self-help (GSH) is an alternative to psychotherapy which requires that the patient take home a standardized psychological treatment and work through it more or less independently. The role of the therapist is primarily of supportive nature and the amount of contact between the patient and therapist is minimized. There is evidence that GSH based on the principles of cognitive-behavioral therapy (GSH-CBT) and guided by a licensed mental health provider is effective for treating GAD in older adults. However, the capacity of our health care system to respond adequately to the mental health needs of older adults has been questioned and cost-effective solutions are required to meet the needs of a rapidly aging population. Because the therapist's role in GSH-CBT is limited to supporting the patient, it is conceivable that this role could be assumed by trained and supervised lay providers (LP) instead of licensed providers. LP are generally providers with no post-graduate training in a specialized mental health program. The main goal of the study is to evaluate the efficacy of GSH-CBT guided by LP for GAD in older adults. Secondary goals are to identify the characteristics of patients associated with improvement during treatment and to document perception of treatment by patients and LP. We will conduct a multisite randomized controlled trial comparing an experimental group receiving GSH-CBT guided by LP to a wait-list control group. LP training will include readings, didactic training, and role plays. LP will be supervised throughout the project by licensed psychologists. Treatment will last 15 weeks and be based on a participant's manual. Weekly telephone sessions with LP (30 minutes maximum) will be limited to providing support. Data will be obtained through clinician evaluations and self-assessment questionnaires. They will include symptoms of GAD and variables related to anxiety, such as depression. For the experimental group, measurements will take place at pre- and post-treatment and at 6 and 12 months post-treatment. For the control group, three evaluations are planned: two pre-treatment evaluations (before and after the waiting period) and after receiving treatment (post-treatment). The efficacy of GSH-CBT will be established by comparing the change in the two groups on the main variables. This project will provide evidence on the effectiveness of a novel approach to treat GAD in older adults. If effective, it may be implemented on a larger scale and provide many older adults with much needed mental health treatment through an expanded workforce.

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montréal, Quebec, Canada, H3W 1W4
        • Centre de recherche de l'Institut universitaire de gériatrie de Montréal
      • Québec, Quebec, Canada, G1V 0A6
        • École de psychologie, Université Laval
      • Sherbrooke, Quebec, Canada, J1K 2R1
        • Département de psychologie, Université de Sherbrooke

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 60 years of age or older
  • meet at least criteria for subthreshold GAD at screening based on items of the Worry and Anxiety Questionnaire
  • meet DSM-5 criteria for primary threshold or subthreshold GAD
  • be able to read and speak French and to use the telephone without difficulty
  • if an anxiety medication is used, commit to maintaining the type of medication or dose during eight weeks prior to treatment and during the protocol.

Exclusion Criteria:

  • a disabling physical disorder that is not adequately controlled (e.g., acute heart disease, recent stroke)
  • the presence of a substance use disorder
  • presenting a bipolar disorder or symptoms of a psychotic disorder
  • having significant cognitive impairment (score of less than 22 on the Telephone version of the Mini-Mental State Examination)
  • currently receiving or having received psychotherapy for anxiety over the last six months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Self-help guided by a lay provider
Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
Other: Waiting list where participants wait for delayed treatment
Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Penn State Worry Questionnaire
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
16 items rated on a scale ranging from 1 to 5. A higher total score indicates a greater tendency to worry.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in GAD-7
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
7 items answered on a scale ranging from 0 to 3. A higher total score suggests greater severity.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Intolerance to Uncertainty Inventory
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
27 items rated on a scale ranging from 1 to 5. A higher total score suggests higher intolerance to uncertainty.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Negative Problem Orientation Questionnaire
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
12 items rated on a scale ranging from 1 to 5. A higher total score suggests more negative attitudes toward problems.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Cognitive Avoidance Questionnaire
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
25 items rated on a scale ranging from 1 to 5. A higher total score suggests more likely use of cognitive avoidance.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Why Worry Questionnaire
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
25 items rated on a scale ranging from 1 to 5. A higher total score suggests a greater belief that worrying is useful.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Geriatric Anxiety Inventory
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
20 items rated as "agree" or "disagree". Minimum score = 0; Maximum score = 20. A higher total score is indicative of greater severity of symptoms.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Geriatric Depression Scale
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
30 items rated as "yes" or "no". Minimum score = 0; Maximum score = 30.A higher total score is indicative of greater severity of symptoms.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Insomnia Severity Index
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
7 items rated on a scale ranging from 1 to 4. A higher total score suggests more severe insomnia.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Sheehan Disability Scale
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Three self-rated items of family, work, and social impairment rated on a scale ranging from 0 to 10.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in Mini-Mental State Examination, telephone version
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Items on orientation to time and place, registration, attention, recall, and language. Scores vary between 0 and 26 with higher scores indicating better cognitive functioning.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Change in GAD diagnosis
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
The Anxiety and Related Disorders Interview Schedule for DSM-5 is a validated structured interview used to confirm the presence or absence of anxiety disorders and associated psychiatric diagnoses.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of treatment by participants
Time Frame: Post treatment (15 weeks)
Measures participant's perception of treatment. 19 statements covering various aspects of treatment (modules, readings, exercises, telephone sessions, workload, organization and duration of treatment, and its usefulness). Each statement is evaluated on a four-point scale ranging from "strongly agree" to "absolutely disagree". A fifth possible answer, 'does not apply', is also provided.
Post treatment (15 weeks)
Questionnaire of behavioral manifestations linked to anxiety
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Twenty-four items evaluating six behaviors related to generalized anxiety, namely reassurance seeking, avoidance, control, procrastination, overplanning and checking. Items are rated on a five point Likert scale
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
Nine items relating to COVID-19
Time Frame: Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.
These items were added to describe the reality of the participants while considering the effects of the pandemic on their anxiety. Five questions are framed as "yes or no" with an open-ended description of their answer choice whereas four items are rated on a five-point Likert scale.
Baseline, post treatment (15 weeks), 6 months and 12 months follow-up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 11, 2019

Primary Completion (Actual)

February 24, 2023

Study Completion (Actual)

February 24, 2023

Study Registration Dates

First Submitted

November 21, 2018

First Submitted That Met QC Criteria

December 5, 2018

First Posted (Actual)

December 7, 2018

Study Record Updates

Last Update Posted (Actual)

October 4, 2023

Last Update Submitted That Met QC Criteria

October 2, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SIRUL 118715

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Anxiety Disorder

Clinical Trials on Self-help guided by a lay provider

3
Subscribe